Biotech Venture Funding Falls to $2.3 Billion in Q3, Avant Bio Says

• Life sciences venture funding fell to $2.3 billion across 64 deals in Q3 2026 from $4.1 billion across 132 deals in Q2.
• Average deal size rose to roughly $36 million as investors concentrated capital in fewer platforms with clinical or commercial traction.
• Later-stage rounds attracted about $2.1 billion, roughly 95% of venture funding; seed and early-stage investment hit five-quarter lows.
• Mergers and acquisitions totaled roughly $3.1 billion across 19 deals, down from $9.8 billion in Q2 despite broadly stable deal volume.
• Strategic buyers targeted consumables, manufacturing capacity and data services, while manufacturing platforms faced greater pressure to demonstrate commercial-scale performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avant Bio LLC published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.